Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1703647 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $10.07Day −4.10%Mkt cap $145M1Y −33.6%Off 52W high −82.0%Vol (1Y) 124.2%
Daily closing price, split-adjusted to the current basis; 2.7y shown of 678 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest10.1% of sh out |
| Days to cover6.4d |
| 13F net flow (QoQ)+8.95% |
| Top-10 13F concentration69.1% |
| Next report (est.)2026-08-06 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$3.8M |
| Earnings (TTM)-$113.5M |
| Net margin−1834.5% |
| ROIC−143.3% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+25.7% |
| 1Y−33.6% |
| Since incept. (ann.)−14.6% |
Total return through 2026-07-29 · series begins 2023-11-06. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)124.2% |
| Ann. volatility (3Y)133.9% |
| Sharpe (1Y)0.63 |
| Sharpe (3Y)0.60 |
| Max drawdown (1Y)−89.7% |
| Max drawdown (3Y)−94.1% |
| Beta (3Y vs SPY)2.30 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| Lynx1 Capital Management LP | 1.5M | $17M | 10.67% | +126.9% |
| NEA Management Company, LLC | 1.3M | $15M | 9.00% | +19.0% |
| Atlas Venture Life Science Advisors, LLC | 1.1M | $13M | 7.88% | +0.0% |
| Balyasny Asset Management L.P. | 1.0M | $12M | 7.21% | new |
| Venrock Adviser, LLC | 1.0M | $11M | 7.00% | new |
| Affinity Asset Advisors, LLC | 706,904 | $8M | 4.90% | new |
| Nantahala Capital Management, LLC | 660,036 | $7M | 4.58% | +10.0% |
| ADAR1 Capital Management, LLC | 540,054 | $6M | 3.74% | new |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-07 | −$1.69 | — | $0 | −100.0% |
| 2025-12-31 | 2026-03-12 | — | — | $1.3M | −43.1% |
| 2025-09-30 | 2025-11-12 | −$1.92 | — | $1.1M | — |
| 2025-06-30 | 2025-08-12 | −$2.74 | — | $1.5M | — |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-06 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
